loader from loading.io

Elizabeth Nielson and Ingmar Gorman - The Importance of Psychedelic Integration Training for Therapists

Psychedelics Today

Release Date: 02/18/2020

PT511 – The Other Side of Veteran Healing: Secondary PTSD and Post-Retreat Family Dynamics, with Allison Wilson & Dr. Grace Blest-Hopley show art PT511 – The Other Side of Veteran Healing: Secondary PTSD and Post-Retreat Family Dynamics, with Allison Wilson & Dr. Grace Blest-Hopley

Psychedelics Today

In this episode, Joe interviews two members of the Heroic Hearts Project team: Director of Donor Development and founder of The Hope Project, Allison Wilson; and Director of Research and founder of Hystelica, Dr. Grace Blest-Hopley. They discuss how The Hope Project – a nonprofit that supports spouses of veterans, Gold Star Wives, and female veterans with scholarships to psychedelic healing retreats, integration, community, etc. – merged with Heroic Hearts Project, and why this is such a necessary part of the veteran healing story: How does a family hold space for a vet returning to a...

info_outline
PT510 – Early Research, Psychedelics in Palliative Care, and the Intersection of Science and the Sacred, with William Richards, STM, Ph.D. show art PT510 – Early Research, Psychedelics in Palliative Care, and the Intersection of Science and the Sacred, with William Richards, STM, Ph.D.

Psychedelics Today

In this episode, Joe and Kyle interview William Richards, STM, Ph.D.: senior advisor at Sunstone Therapies, psychologist at the Center for Psychedelic and Consciousness Research at the Johns Hopkins School of Medicine, contributor to Vital, and author of . He talks about the first time he experienced psilocybin in a research study in 1963, his early studies on the psychology of religion, working with Abraham Maslow, how he became one of the early psychedelic therapists, and what it was like for all of that to disappear when Nixon came into office and shut everything down. He...

info_outline
PT509 – Music for Psychedelic Exploration, and the First 'Choose Your Own Adventure' Album, with Shahar Amit show art PT509 – Music for Psychedelic Exploration, and the First 'Choose Your Own Adventure' Album, with Shahar Amit

Psychedelics Today

In this episode, Joe interviews Shahar Amit: psytrance musician who has created what may be the world's first modular album for psychedelic exploration under his project, Held By Sound.  He talks about his background in the rave and festival scene, the moment he realized he wanted to make music, and the realization that he could create soundscapes specifically for journeys into non-ordinary states. And he digs into the 'choose your own adventure' framework of the free album: how he actually recorded 3 different albums and figured out how to transition into different moods based on which...

info_outline
PT508 – The Veteran Community and Operator Syndrome: Psychedelics and Redefining Pain Management, with Tommy Aceto show art PT508 – The Veteran Community and Operator Syndrome: Psychedelics and Redefining Pain Management, with Tommy Aceto

Psychedelics Today

In this episode, Joe and special guest, Court Wing, interview Tommy Aceto: former Navy Seal and trauma medic, NCAA athlete, Michigan State Champion Wrestler, and now, psychedelic advocate and ambassador for the Veteran Mental Health Leadership Coalition. He discusses his journey from childhood to wanting to become a SEAL, and the toll that military life and its programming can take on a person: how a life built on high levels of endurance, deprivation, and constantly surviving in a fight-or-flight mindset often manifests in Operator Syndrome, chronic pain, depression, and addiction. Veterans...

info_outline
PT507 – Psychedelic Education: Insights, Advice, and Where to Start, with Johanna Hilla & Kyle Buller show art PT507 – Psychedelic Education: Insights, Advice, and Where to Start, with Johanna Hilla & Kyle Buller

Psychedelics Today

In this episode, Kyle and Johanna catch up, interviewing each other about psychedelic education and what they’ve learned, the biggest challenges, and what advice they would give to anyone looking to get involved in the psychedelic field. They discuss: How sometimes it’s not about the substance: If you want to be a psychedelic therapist, do you see yourself doing therapy without the psychedelics? How no part of education is exempt, and becoming truly psychedelically-competent can involve studying psychology, neuroscience, somatics, religion, history, etc. How people’s experiences are...

info_outline
PT506 – Decolonization, Difficult Conversations, and the Challenge of Merging Spirituality and Science, with Philip Wolf show art PT506 – Decolonization, Difficult Conversations, and the Challenge of Merging Spirituality and Science, with Philip Wolf

Psychedelics Today

In this episode, Joe interviews Philip Wolf: writer, member of Rolling Stone's Culture Council, founder of Cultivating Spirits (the first company in the U.S. to offer legal culinary cannabis experiences), and founder of CashoM, an education company offering a certificate in cannabis stewardship. He discusses his recent Rolling Stone article about the need to divorce ourselves from the colonial mindset that pervades the psychedelic movement, and he talks about the difficult conversation that came about when he asked a very critical group of psychedelic leaders how they felt about the article,...

info_outline
PT505 – Bicycle day Reflections, Quantum Mechanics, and the Value in Studying Philosophy to Understand Psychedelic Experiences, with Lenny Gibson, Ph.D. show art PT505 – Bicycle day Reflections, Quantum Mechanics, and the Value in Studying Philosophy to Understand Psychedelic Experiences, with Lenny Gibson, Ph.D.

Psychedelics Today

In this episode, Joe and Kyle interview Lenny Gibson, Ph.D.: philosopher, Grof-certified Holotropic Breathwork® facilitator, 20-year professor of transpersonal psychology at Burlington College, and the reason Joe and Kyle met many years ago. He talks about his early LSD experiences and how his interest in the philosophy of Plato and Alfred North Whitehead provided a framework and language for understanding a new mystical world where time and space were abstractions. He believes that while culture sees the benefits of psychedelics in economic terms, the biggest takeaway from non-ordinary...

info_outline
PT504 – Rethinking Drug Education: From D.A.R.E. Scare Tactics to an Evidence-Based Approach, with Joey Lichter, Ph.D. show art PT504 – Rethinking Drug Education: From D.A.R.E. Scare Tactics to an Evidence-Based Approach, with Joey Lichter, Ph.D.

Psychedelics Today

In this episode, Joe interviews Joey Lichter, Ph.D.: professor in the Chemistry & Biochemistry department at Miami’s Florida International University, and one of the few professors in the U.S. teaching a course about psychedelics at the collegiate level. He talks about his path towards the course, the challenge of creating a curriculum that covers everything in a few months, and the importance of teaching young minds about psychedelics the right away; shifting drug education from the “Just say no!” D.A.R.E. model to a more balanced, honest, and evidence-based approach. He aims for...

info_outline
PT503 – Updates from MAPS: Current Initiatives, Psychedelic Science 2025, and Music as a Bridge, with Devon Phillips show art PT503 – Updates from MAPS: Current Initiatives, Psychedelic Science 2025, and Music as a Bridge, with Devon Phillips

Psychedelics Today

In this episode, Joe interviews Devon Phillips: community & partnerships officer for the Multidisciplinary Association for Psychedelic Studies (MAPS). Phillips works on strategies to tackle the questions: How do we responsibly mainstream psychedelics? And how do we get culture engaged? He's focusing on being the bridge to psychedelics outside of research, facilitating workshops and psychedelic coming-out stories at music festivals and conferences. He talks about harm reduction and drug checking at festivals, the concept of training big names to become trustworthy resources, the differences...

info_outline
PT502 – Preserving Psychedelic Legacies: Shulgin Farm and the Shulgin Archive Project, with Keeper Trout show art PT502 – Preserving Psychedelic Legacies: Shulgin Farm and the Shulgin Archive Project, with Keeper Trout

Psychedelics Today

In this episode, Joe interviews Keeper Trout: archivist, author, photographer, co-founder of the Cactus Conservation Institute, and creator of Trout’s Notes, a website compiling personal research and collected data to help ethnobotanical researchers. From an interest in cactus taxonomy, Sasha Shulgin urged Trout to go through his files, resulting in a friendship, and eventually, an 8-year project of digitizing all of these files into the ever-evolving Shulgin Archive. Trout discusses: His relationship with Sasha and The Shulgin Farm project, which aims to make the farm a community resource...

info_outline
 
More Episodes

In this Episode, Kyle sits down with Elizabeth Nielson and Ingmar Gorman, Co-founders of Fluence, Training in Psychedelic Integration. They are both therapists on the MAPS clinical trial for MDMA Assisted Psychotherapy for PTSD.

3 Key Points:

  1. Elizabeth and Ingmar are co-founders of Fluence, an online Psychedelic Integration Training program.
  2. If psychedelic treatments become available more widely, the fear is that therapists won't be as educated on how to handle their patient interactions based on the behavior of each psychedelic. Psychedelic Integration Therapy Training is so important.
  3. There are 3 phases to the MDMA for PTSD clinical trial. Phase 1 would be pre-clinical data about the chemistry of a drug, Phase 2 is where you begin to test your treatment in a patient population, and Phase 3 is where you get the data to demonstrate that the treatment is superior to a placebo and other treatments in general.

Support the show

Navigating Psychedelics


Show Notes

About Ingmar

  • Ingmar is a previous guest of the show
  • He is a private Investigator for the MAPS MDMA trial
  • He is a therapist and the Co-founder of Fluence

About Elizabeth

  • Elizabeth is a Clinical Psychologist
  • She has a long history in working with clinical trials as a therapist
  • She is part of the psychedelic education and continuing care program
  • She does a lot of supervision and training for therapists

The Trial

  • The approval of expanded access by the FDA includes 50 people in total
  • They are near the end of MAP 1 (out of MAP 1 and MAP 2)
    • When they transition into MAP 2, it will be a little more refined
    • MAP 2 is different participants than MAP 1
  • There are 3 phases
    • Phase 1 would be pre-clinical data about chemistry of a drug and how it metabolises, if its poisonous, etc
    • Phase 2 is where you begin to test your treatment in a patient population
    • Phase 3 is where you get the data to demonstrate that the treatment is superior to a placebo and other treatments in general
    • They are done as a double-blind trial, both the therapist and patient don't know if the patient is receiving the treatment or now

Take-aways

  • There is a lot of information that has to be shared effectively
  • The therapists are very much in the lives of the participants on top of just the MDMA
  • Instead of learning from the trials of what to do on a practical level, its about inspiring them to bring this as an actual treatment for people
  • The multiple ways that PTSD can manifest and look like, and the may ways that MDMA can look like when administered, have some commonalities
    • The deepening, the broadening, the way they communicate, can all be the same
  • Ingmar holds the belief in the inner healing intelligence of all people
    • One of the first things he does when he begins with a new patient, he says that this is something he really believes in, and his role as a therapist to help them in their own healing process and mechanism
  • What Elizabeth wanted to learn, know and practice while she was going through school, isn't what she she thought it was until she found it
    • She says this work really requires them to trust people's minds and experiences
    • There is something that they tell their patients, “Don't get ahead of the medicine” - Elizabeth
  • There is an interesting paradox between not knowing and following intuition, to having an actual method and following that
    • There is a sweet spot between following a script to following your intuition as a therapist
    • You want to trust that inner healer process of the patient, but also need to know when to intervene (usually from a safety standpoint)

Fluence

  • 3 days after Horizons, Elizabeth was at home with a cold, and talked to Ingmar that morning curious for a name for the project
  • Fluence means, magical or mystical power or source of power
    • It can also refer to the density of particles of energy
  • They teach about harm reduction and integration with their patients in their practice
    • They aren't teaching protocols in the workshops, they just think the harm reduction is important
  • The last part of integration is mindfulness
  • Ingmar’s biggest influence are his clients and patients, he is so inspired by them
    • A large piece of the motivation for creating Fluence is from patients just looking for someone to talk about their experience with

The Why

  • A mother whose teenage daughter with depression, reached out to Ingmar with trouble trying to treat her depression
    • The family decided it would be a good idea to use Ketamine therapy, which was successful
    • She was doing so well, so well that she then went to a therapist to integrate it
    • The therapist that she went to then instead of responding positively, decided to fire the teen for further therapy, and report the parents to child care services for providing ketamine therapy
    • Ingmar says their position is not that everyone needs psychedelic integration therapy, its specifically for those that don't feel supported by family or community, and it gives them a professional service as an option
  • "Psychedelics are not 10 years of change in one night, they are 10 years of insight in one night. integration is so important." - Elizabeth
  • The goal is to support people in making a change that feels safe and right for them
  • If the treatments become available more widely, the fear is that therapists won't be as educated on how to handle their patient interactions based on the behavior of each psychedelic
    • Mental health practitioners can be a great source for working through those experiences

Menla Training

  • Menla Training
  • They could really take their time with the process and training
  • The trainings that they had gone to has made their own Fluence courses better
  • In 2019 they had 5 of the trainings for clinicians, and the trainings will be better and better as they go

Ketamine Infusion Therapy

  • The experience is not dose dependent
  • The purpose of the workshop is to educate both therapists and doctors about what can happen in psychotherapy

Links

Fluence

Psychedelics 101 and 102 Workshop at ICPR 2020


About Elizabeth

Dr. Elizabeth Nielson is a co-founder of Fluence and a psychologist with a focus on developing psychedelic medicines as empirically supported treatments for PTSD, substance use problems, and mood disorders. Dr. Nielson is a therapist on FDA approved clinical trials of psilocybin-assisted treatment of alcohol use disorder, MDMA-assisted treatment PTSD, and psilocybin-assisted treatment of treatment resistant depression. Through Fluence, she provides continuing education and training programs for therapists who wish to engage in integration of psychedelic experiences in clinical settings. Her program of research includes qualitative and mixed-methods projects designed to further understand the phenomenology and mechanisms of change in psychedelic-assisted therapy, including the experiences of trial participants and of the therapists themselves. Having completed an NIH postdoctoral fellowship at NYU, she has published and presented on topics of psychedelic therapist training, therapists’ personal experience with psychedelics, and including psychedelic integration in group and individual psychotherapy.

About Ingmar

Dr. Ingmar Gorman is a co-founder of Fluence and a psychologist who specializes in assisting populations who have a relationship with psychedelics. He is the site co-principal investigator and therapist on a Phase 3 clinical trial studying MDMA-assisted psychotherapy for post-traumatic stress disorder. Dr. Gorman is a board member of Horizons Media, Inc., a not for-profit educational charity and organizer of the Horizons Conference: Perspectives on Psychedelics. After completing his NIH postdoctoral fellowship at New York University, Dr. Gorman stepped down as director of the Psychedelic Education and Continuing Care Program to focus his efforts on Fluence and the training of future therapists.

Designed to help the body with cellular energy and cardiovascular endurance.

Get a 30 day free audible trial at audibletrial.com/psychedelicstoday